Want to see KIDS full AI Analyst Report?
KIDS Stock Chart & Stats
$24.50
$0.95(5.03%)
At close: 4:00 PM EDT
$24.50
$0.95(5.03%)
Day’s Range― - ―
52-Week Range$14.42 - $26.74
Previous Close$20.42
Volume117.04K
Average Volume (3M)190.35K
Market Cap
$565.28M
Enterprise Value$518.17M
Total Cash (Recent Filing)$45.88M
Total Debt (Recent Filing)$91.59M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Nov 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding26,109,789
10 Day Avg. Volume186,226
30 Day Avg. Volume190,348
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.78
Enterprise Value/Ebitda-114.06
Forecast
1Y Price Target
$27.50Price Target Upside12.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$266.98M
Bulls Say, Bears Say
Bulls Say
Pediatric Specialization And Market PositionA pediatric-only platform and specialized product portfolio can deepen surgeon and hospital relationships in a focused market where adult-oriented incumbents leave a competitive gap. Broad access across leading children’s hospitals and more than 75 countries supports durable adoption and international expansion.
Strong Growth And Gross-margin DurabilityStrong multi-year revenue expansion combined with consistently high gross margins indicates meaningful demand and favorable economics in the company’s specialized offerings. Stable gross profitability provides resources to fund product launches, commercial expansion, and eventual operating leverage as scale increases.
Raised Outlook And Improving Cash GenerationHigher revenue guidance, record quarterly adjusted EBITDA, and a stated path to full-year free-cash-flow break-even indicate improving operating leverage. If execution continues, stronger internal cash generation should reduce reliance on financing and support continued investment in the product portfolio.
Bears Say
Persistent Operating And Net LossesThe company has not yet converted strong gross profits into sustainable operating or net earnings, and losses have persisted across most reported years. This weakens earnings quality, limits internally funded growth, and leaves results more dependent on continued revenue expansion and expense discipline.
Free Cash Flow Remains NegativePositive operating cash flow is encouraging, but negative free cash flow shows that reinvestment and capital needs still exceed internally generated cash. Until free cash flow becomes consistently positive, the business has less flexibility to fund expansion, absorb setbacks, or reduce dependence on available liquidity.
Debt Has Increased From Earlier YearsAlthough current leverage remains conservative, higher debt than in earlier years introduces a gradual increase in financial obligations while the company is still loss-making and free cash flow negative. This can constrain capital allocation and increase reliance on balance-sheet capacity if the path to profitability takes longer.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
OrthoPediatrics Corp lowest stock price was $14.42 and its highest was $26.74 in the past 12 months.
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $565.28M.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Nov 03, 2026 which is in 23 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.002.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -0.23.
How many shares outstanding does OrthoPediatrics Corp have?
OrthoPediatrics Corp has 26,109,789 shares outstanding.
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went up 6.849%.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (12.24% Upside)
$27.50 (12.24% Upside)
Blogger Sentiment
Neutral
KIDS Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 254.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.61%
12-Months-Change
Fundamentals
Return on Equity
-11.53%
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.View all KIDS earnings summariesKIDS Stock 12 Month Forecast
Average Price Target
$27.50
▲(12.24% Upside)
Technical Analysis
Alphatec Holdings
―
Enovis
―
Orthofix Medical
―
Zimmer Biomet Holdings
―
Globus Medical
―
Ownership Overview
32.84% Insiders
12.87% Mutual Funds
23.00% Other Institutional Investors
23.29% Public Companies and
Individual Investors